Topos Bio

Topos Bio, founded in 2025, operates out of San Francisco, US. The company is dedicated to drug discovery by leveraging an advanced AI-driven platform.Topos Bio is focused on revolutionizing drug discovery through its advanced AI-native platform, specifically targeting intrinsically disordered proteins (IDPs), which play a significant role in diseases such as Alzheimer's and prostate cancer. The company’s flagship product, Topos-1, is an all-atom foundation model designed to generate physically realistic conformational ensembles for flexible proteins. This model enables researchers to analyze protein dynamics more effectively, unlocking new opportunities to address previously deemed "undruggable" targets in the pharmaceutical landscape. Topos Bio primarily collaborates with research institutions and biotechnology firms, including partnerships with organizations like the Gladstone Institutes.Topos Bio's revenue model is structured around partnerships and collaborations with academic institutions and biotech companies that seek to leverage its cutting-edge technology for drug discovery. The company engages in B2B transactions, focusing on providing access to its proprietary drug discovery platform and tools, including the Topos-1 model. These agreements may involve licensing fees or subscription-based access to the platform, facilitating ongoing collaboration and integration of Topos's technology into clients’ research workflows. The company aims to refine its Topos-1 model for intrinsically disordered proteins and expand its generative chemistry capabilities. Plans include validating these advancements through wet lab experiments, targeting treatments for Alzheimer’s and cancer. Topos Bio is also exploring expansion into additional markets, particularly in Europe, to enhance its reach in pharmaceutical research by 2027.

1. Seed

   Jan 8, 2026

   Amount

   $11M

   Investors

   Locked